☰
✕

Cancer chemotherapy associated nausea and vomiting therapeutics market

Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type (Acute CINV, Delayed CINV, Anticipatory nausea and emesis and Breakthrough CINV/Refractory CINV), By Drug Class (Dopamine Receptor Antagonists (Metoclopramide, Chlorpromazine, Prochlorperazine, Haloperidol, Droperidol and Others), Serotonin (5-HT3) receptor Antagonists (Ondansetron, Granisetron, Palonosetron, Dolasetron and others), Substance P/NK-1 Antagonists (Aprepitant, Fosaprepitant, Netupitant, and Others), Corticosteroids (Dexamethasone and Methylprednisolone) and others), By Route of Administration (Oral, Parenteral and Transdermal Patch), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Request Free Sample
  • Jun 2023
  • CMI5823
  • 266 Pages
  • Excel & Pdf
  • Pharmaceutical

Chemotherapy-induced nausea and vomiting (CINV)  is one of the most serious and dreaded adverse effects of cancer treatment . Up to 70%–80% of patients have been said to have the condition. Antiemetics often have less success reducing nausea, and the incidence of nausea is typically higher than that of real vomiting. There are several different types of CINV, including anticipatory, acute, delayed, breakthrough, and refractory. Chemotherapeutic regimens can be grouped into those with high, moderate, low, or little emetogenicity risk. The frequency and timing of CINV varies depending on the patient's characteristics and the chemotherapeutic drugs. Weakness, weight loss, dehydration, anorexia, a reduction in mental state, as well as a number of other issues, can be serious side effects of CINV. Emesis and nausea are still common side effects of chemotherapy, despite the emergence of more potent antiemetic medications. For the benefit of patients, it is crucial to understand the mechanism behind CINV, recognize those who are more at risk, and discover and develop efficient antiemetic therapies. This field of research is still quite active.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market is estimated to be valued at US$ 3,071.1 Million in 2023, exhibiting a CAGR of 5.7% during the forecast period (2023-2030).

Analysts’ Views on Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market growth can be hindered by high cost of chemotherapy-induced nausea and vomiting (cinv) treatment drugs. For instance, according to GoodRx, Inc., a healthcare company that operates a telemedicine platform and a free-to-use website and mobile app that track prescription drug prices in the U.S., the average retail price of 1 capsule Akynzeo (Netupitant and Palonosetron Capsules) is around US$ 570.8.

Figure 1. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Share (%), By Type, 2023

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market– Drivers

Rising Cancer Prevalence will Increase the Number of Chemotherapies

Rising cancer prevalence will increase the number of chemotherapies is expected to drive the global cancer chemotherapy associated nausea and vomiting therapeutics market growth over the forecast period. For instance, according to the data provided by the World Health Organization, in February 2022, the most common types of cancer were breast cancer accounting for 2.26 million cases and lung cancer accounting for 2.21 million cases in the year 2020, globally. Moreover, according to the data provided by the World Health Organization in February 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.

Figure 2. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Share (US$ Million), By Region, 2023

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market - Regional Analysis

Among region, North America is estimated to hold a dominant position in the global cancer chemotherapy associated nausea and vomiting therapeutics market over the forecast period. North America holds 44.6% of the market share, due to increasing adoption of inorganic strategies such as distribution and supply agreements by key players in North America region. For instance, in May 2022, Knight Therapeutics Inc., a Canada-based specialty pharmaceutical company, through one of its wholly-owned subsidiaries, and Helsinn Healthcare SA, a global biopharma company, announced that they had entered into an exclusive license, distribution, and supply agreement for AKYNZEO oral/IV (netupitant/palonosetron/ fosnetupitant/palonosetron) in Canada, Brazil, Argentina, Uruguay, and Paraguay, and ALOXI oral/IV (palonosetron) in Canada. AKYNZEO is 5-HT3 and NK1 receptor antagonist fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. ALOXI solution for injection is marketed in Canada for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy and highly emetogenic cancer chemotherapy, including high-dose cisplatin in adults. Under the terms of the agreement, Knight Therapeutics Inc. will have the exclusive right to distribute, promote, market, and sell the products in the licensed territories.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative economic impact on the global cancer chemotherapy associated nausea and vomiting therapeutics market, owing to interruption in the people visits to the hospitals due to lockdown and decreasing cancer diagnosis rates. For instance, according to a data published, in August 2020, by Cancer Connect, during the COVID-19 pandemic, globally there was 46% decrease in the diagnoses of six most common cancer types-breast, colorectal, lung, pancreatic, gastric, and esophageal cancers.

Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 3,071.1 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 to 2030
Forecast Period 2023 to 2030 CAGR: 5.7% 2030 Value Projection: US$ 4,521.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Bag Size: 5mm, 10mm, 15mm, 25mm
  • By Product Type: Detachable, Non-detachable
  • By Application: Gynecology, Urology, Gastrointestinal Surgery, Others (Cardiovascular, etc.)
  • By End User: Hospital, Ambulatory Surgical Centers, Nursing Homes
Companies covered:

Johnson & Johnson Services, Inc., Teleflex Incorporated, Cooper Surgical, Inc., Genicon, Medtronic, B. Braun SE, Applied Medical Resources Corporation, LaproSurge, Purple Surgical, CONMED, Hangzhou Boer Medical Instruments Co., Ltd., Duomed, Changzhou Cheayoo Medical Devices Co., Ltd., and Tianjin Zhichao Medical Technology Co., Ltd
Growth Drivers:
  • Increasing prevalence of gynecological disorders 
Restraints & Challenges:
  • Increasing number of product recall by regulatory authorities 

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market- Segmentation

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market  is segmented into Type, Drug Class, Route of Administration and Distribution Channel

Based on Type, the market is segmented into acute CINV, delayed CINV, anticipatory nausea and emesis, breakthrough CINV/refractory CINV. Out of which, the delayed CINV segment is expected to hold a dominant position in the global cancer chemotherapy associated nausea and vomiting therapeutics market during the forecast period, owing to increasing research and development activities for delayed CINV.

Based Drug Class, the market is segmented into dopamine receptor antagonists, serotonin (5-HT3) receptor antagonists, substance P/NK-1 antagonists, corticosteroids and others. Out of which, the serotonin (5-HT3) receptor antagonists segment is expected to hold a dominant position in the global cancer chemotherapy associated nausea and vomiting therapeutics market during the forecast period, owing to Increasing launches of serotonin (5-HT3) receptor antagonists.

Based Route of Administration, the market is segmented into oral, parenteral  and transdermal patch. Out of which, the oral segment is expected to hold a dominant position in the global cancer chemotherapy associated nausea and vomiting therapeutics market during the forecast period, owing to increasing oral drug launches to treat CINV.

Based on Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period, owing to launching pharmacies.

Among all segmentation, the delayed CINV segment has the highest potential due to increasing research and development activities.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market- Cross Sectional Analysis

Among end user, Hospital Pharmacies segment hold a dominant position in North America Region. Hospitals are focused on launching pharmacies, which is expected to drive the segment growth over the forecast period. For instance, in September 2022, Apollo Pharmacy, a part of The Apollo Hospitals Group, announced the launch of its 5,000th store in India, which is situated at Perungudi, Old Mahabalipuram Road in Chennai

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market- Key Developments

In May 2021, Tetra Bio-Pharma Inc., a company involved in cannabinoid-derived drug discovery and development, announced that the company had been granted a Health Canada Drug Establishment License (DEL) to distribute REDUVO soft gel capsules in Canada. REDUVO is a synthetic tetrahydrocannabinol-based soft gel capsule indicated in severe nausea and vomiting associated with cancer chemotherapy.

In September 2020, Sandoz announced the launch of generic antiemetic medicine Fosaprepitant injection 150 mg in the U.S., enhancing hospital offerings and strategically expanding its injectables portfolio. Fosaprepitant is an antiemetic drug used in adults for the prevention of nausea and vomiting associated with certain chemotherapies.

In December 2020, Jupiter Wellness, Inc., a pharmaceutical company, signed a definitive agreement to merge with Next Frontier Pharmaceuticals, Inc., a drug developer and manufacturer of synthetic cannabinoid pharmaceuticals. Next Frontier Pharmaceuticals owns the only U.S. FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid, SYNDROS, used in adults to treat chemotherapy-induced nausea and vomiting.

In February, 2020, Camber Pharmaceuticals Inc., a fully integrated international pharmaceutical company, announced the launch of Dronabinol capsules to its portfolio of products. Dronbinol is used to treat nausea and vomiting caused by cancer chemotherapy.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market : Key Trends

Increasing Government Intiatives for Improving Cancer Care

Increasing government initiatives to establish cancer care centers is expected to drive the global cancer chemotherapy associated nausea and vomiting therapeutics market growth over the forecast period. For instance, in August 2022, the Prime Minister of India, Narendra Modi inaugurated Homi Bhabha Cancer Hospital & Research Centre at Mohali in Punjab, India. It is a 300-bed capacity and is equipped with modern facilities to treat all types of cancers using every available treatment modalities such as surgery, radiotherapy and medical oncology- chemotherapy, bone marrow transplant, and immunotherapy. It is a part of Pradhan Mantri Swasthya Suraksha Yojana, a program implemented by the Union Ministry of Health and Family Welfare, India, with an aim to correct imbalances in the availability of tertiary healthcare services and improve the quality of medical education.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market : Restraint

Poor Reimbursement Policies

Poor reimbursement policies and healthcare financing structures in low economies such as Middle East is expected to act as a restraint for the market growth over the forecast period. For instance, according to an article published by the European Medical Journal, in August 2020, antiemetic guidelines are valid in countries where drugs are available and reimbursed; however, this is not the case in some parts of the world.

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market - Key Players

Major players operating in the global cancer chemotherapy associated nausea and vomiting therapeutics market are Eisai Co., Ltd., Pharmanovia, Novartis AG, Merck & Co., Inc., Helsinn Healthcare SA, Dr. Reddy’s Laboratories Ltd., Validus Pharmaceuticals LLC, LGM Pharma, Astellas Pharma Inc., AdvaCare Pharma, Norgine, PV Pharma, Fresenius Kabi, Lupin, Hetero Healthcare Limited., Sino Biopharmaceutical Limited, Glenmark Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, OPKO Health, Inc., Weefsel Pharma, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Starton Therapeutics.

*Definition: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of cancer treatment. Nausea and vomiting are the most feared, as well as the most common adverse effects among patients undergoing chemotherapy

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Type
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
    • PORTER’s Analysis
    • Regulatory Scenario
    • Merger, Collaboration and Acquisition Scenario
    • Product Launches/Approvals
    • Epidemiology
  4. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market– COVID-19 Impact Analysis
    • Economic Impact
    • Overall Impact on Healthcare Sector
    • COVID-19 Epidemiology
  5. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type, 2018 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Acute CINV
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
    • Delayed CINV
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
    • Anticipatory nausea and emesis
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
    • Breakthrough CINV/Refractory CINV
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
  6. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Drug Class, 2018 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Dopamine Receptor Antagonists
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
        • Metoclopramide
        • Chlorpromazine
        • Prochlorperazine
        • Haloperidol
        • Droperidol
        • Others
    • Serotonin (5-HT3) receptor Antagonists
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
        • Ondansetron
        • Granisetron
        • Palonosetron
        • Dolasetron
        • Others
    • Substance P/NK-1 Antagonists
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
        • Aprepitant
        • Fosaprepitant
        • Netupitant
        • Others
    • Corticosteroids
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
        • Dexamethasone
        • Methylprednisolone
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
  7. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Route of Administration, 2018 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Oral
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
    • Parenteral
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
    • Transdermal Patch
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
  8. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Distribution Channel, 2018 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
    • Online Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Million)
  9. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Region, 2018 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Million)
        • UK
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Million)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Type, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018–2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  10. Competitive Landscape
    • Eisai Co., Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pharmanovia
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlight
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck & Co., Inc.
      • Company Highlight
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Helsinn Healthcare SA
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Reddy’s Laboratories Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Validus Pharmaceuticals LLC
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • LGM Pharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Astellas Pharma Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AdvaCare Pharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Norgine
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • PV Pharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Fresenius Kabi
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Lupin
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Hetero Healthcare Limited.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sino Biopharmaceutical Limited
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Glenmark Pharmaceuticals Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Otsuka Pharmaceutical Co., Ltd
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • OPKO Health, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Weefsel Pharma
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Rosemont Pharmaceuticals Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Starton Therapeutics
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  11. Section
    • Research Methodology
    • About Us

*Browse 45 market data tables and 39 figures on "Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market” - forecast to 2030

Detailed Segmentation:

  • Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, Type:
    • Acute CINV
    • Delayed CINV
    • Anticipatory nausea and emesis
    • Breakthrough CINV/Refractory CINV
  • Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, Drug Class:
    • Dopamine Receptor Antagonists
      • Metoclopramide
      • Chlorpromazine
      • Prochlorperazine
      • Haloperidol
      • Droperidol
      • Others
    • Serotonin (5-HT3) receptor Antagonists
      • Ondansetron
      • Granisetron
      • Palonosetron
      • Dolasetron
      • Others
    • Substance P/NK-1 Antagonists
      • Aprepitant
      • Fosaprepitant
      • Netupitant
      • Others
    • Corticosteroids
      • Dexamethasone
      • Methylprednisolone
    • Others
  • Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Route of Administration:
    • Oral
    • Parenteral
    • Transdermal Patch
  • Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Region:
    • North America
      • By Type
        • Acute CINV
        • Delayed CINV
        • Anticipatory nausea and emesis
        • Breakthrough CINV/Refractory CINV
      • By Drug Class
        • Dopamine Receptor Antagonists
          • Metoclopramide
          • Chlorpromazine
          • Prochlorperazine
          • Haloperidol
          • Droperidol
          • Others
        • Serotonin (5-HT3) receptor Antagonists
          • Ondansetron
          • Granisetron
          • Palonosetron
          • Dolasetron
          • Others
        • Substance P/NK-1 Antagonists
          • Aprepitant
          • Fosaprepitant
          • Netupitant
          • Others
        • Corticosteroids
          • Dexamethasone
          • Methylprednisolone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
        • Transdermal Patch
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Type
        • Acute CINV
        • Delayed CINV
        • Anticipatory nausea and emesis
        • Breakthrough CINV/Refractory CINV
      • By Drug Class
        • Dopamine Receptor Antagonists
          • Metoclopramide
          • Chlorpromazine
          • Prochlorperazine
          • Haloperidol
          • Droperidol
          • Others
        • Serotonin (5-HT3) receptor Antagonists
          • Ondansetron
          • Granisetron
          • Palonosetron
          • Dolasetron
          • Others
        • Substance P/NK-1 Antagonists
          • Aprepitant
          • Fosaprepitant
          • Netupitant
          • Others
        • Corticosteroids
          • Dexamethasone
          • Methylprednisolone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
        • Transdermal Patch
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type
        • Acute CINV
        • Delayed CINV
        • Anticipatory nausea and emesis
        • Breakthrough CINV/Refractory CINV
      • By Drug Class
        • Dopamine Receptor Antagonists
          • Metoclopramide
          • Chlorpromazine
          • Prochlorperazine
          • Haloperidol
          • Droperidol
          • Others
        • Serotonin (5-HT3) receptor Antagonists
          • Ondansetron
          • Granisetron
          • Palonosetron
          • Dolasetron
          • Others
        • Substance P/NK-1 Antagonists
          • Aprepitant
          • Fosaprepitant
          • Netupitant
          • Others
        • Corticosteroids
          • Dexamethasone
          • Methylprednisolone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
        • Transdermal Patch
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type
        • Acute CINV
        • Delayed CINV
        • Anticipatory nausea and emesis
        • Breakthrough CINV/Refractory CINV
      • By Drug Class
        • Dopamine Receptor Antagonists
          • Metoclopramide
          • Chlorpromazine
          • Prochlorperazine
          • Haloperidol
          • Droperidol
          • Others
        • Serotonin (5-HT3) receptor Antagonists
          • Ondansetron
          • Granisetron
          • Palonosetron
          • Dolasetron
          • Others
        • Substance P/NK-1 Antagonists
          • Aprepitant
          • Fosaprepitant
          • Netupitant
          • Others
        • Corticosteroids
          • Dexamethasone
          • Methylprednisolone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
        • Transdermal Patch
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type
        • Acute CINV
        • Delayed CINV
        • Anticipatory nausea and emesis
        • Breakthrough CINV/Refractory CINV
      • By Drug Class
        • Dopamine Receptor Antagonists
          • Metoclopramide
          • Chlorpromazine
          • Prochlorperazine
          • Haloperidol
          • Droperidol
          • Others
        • Serotonin (5-HT3) receptor Antagonists
          • Ondansetron
          • Granisetron
          • Palonosetron
          • Dolasetron
          • Others
        • Substance P/NK-1 Antagonists
          • Aprepitant
          • Fosaprepitant
          • Netupitant
          • Others
        • Corticosteroids
          • Dexamethasone
          • Methylprednisolone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
        • Transdermal Patch
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type
        • Acute CINV
        • Delayed CINV
        • Anticipatory nausea and emesis
        • Breakthrough CINV/Refractory CINV
      • By Drug Class
        • Dopamine Receptor Antagonists
          • Metoclopramide
          • Chlorpromazine
          • Prochlorperazine
          • Haloperidol
          • Droperidol
          • Others
        • Serotonin (5-HT3) receptor Antagonists
          • Ondansetron
          • Granisetron
          • Palonosetron
          • Dolasetron
          • Others
        • Substance P/NK-1 Antagonists
          • Aprepitant
          • Fosaprepitant
          • Netupitant
          • Others
        • Corticosteroids
          • Dexamethasone
          • Methylprednisolone
        • Others
      • By Route of Administration
        • Oral
        • Parenteral
        • Transdermal Patch
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Regions
        • South Africa
        • Central Africa
        • North Africa
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global cancer chemotherapy associated nausea and vomiting therapeutics market during the forecast period (2023-2030)?

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market is estimated to be valued at US$ 3,071.1 million in 2023, exhibiting a CAGR of 5.7% between 2023 and 2030.

What are the major factors driving the market growth?

Increase in number of patients undergoing chemotherapy and introduction of novel drug delivery methods to increase patient compliance is expected to drive the market growth.

Which is the leading type segment in the market?

Delayed CINV is the leading type segment in the market.

What are the key factors hampering the growth of the market?

Cost of chemotherapy-induced nausea and vomiting (cinv) treatment drugs is expected to hinder the market growth over the forecast period.

Which are the major players operating in the market?

Major players operating in the market include Eisai Co., Ltd., Pharmanovia, Novartis AG, Merck & Co., Inc., Helsinn Healthcare SA, Dr. Reddy’s Laboratories Ltd., Validus Pharmaceuticals LLC, LGM Pharma, Astellas Pharma Inc., AdvaCare Pharma, Norgine, PV Pharma, Fresenius Kabi, Lupin, Hetero Healthcare Limited., Sino Biopharmaceutical Limited, Glenmark Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, OPKO Health, Inc., Weefsel Pharma, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Starton Therapeutics.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now